Open Access
Performance standards for antimicrobial susceptibility testing
Reads0
Chats0
TLDR
The supplemental information presented in this document is intended for use with the antimicrobial susceptibility testing procedures published in the following Clinical and Laboratory Standards Institute (CLSI)–approved standards.Abstract:
The supplemental information presented in this document is intended for use with the antimicrobial susceptibility testing procedures published in the following Clinical and Laboratory Standards Institute (CLSI)–approved standards: M02-A12—Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard—Twelfth Edition; M07-A10—Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard—Tenth Edition; and M11-A8—Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard— Eighth Edition. The standards contain information about both disk (M02) and dilution (M07 and M11) test procedures for aerobic and anaerobic bacteria. Clinicians depend heavily on information from the microbiology laboratory for treatment of their seriously ill patients. The clinical importance of antimicrobial susceptibility test results demands that these tests be performed under optimal conditions and that laboratories have the capability to provide results for the newest antimicrobial agents. The tabular information presented here represents the most current information for drug selection, interpretation, and QC using the procedures standardized in the most current editions of M02, M07, and M11. Users should replace the tables published earlier with these new tables. (Changes in the tables since the previous edition appear in boldface type.) Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. 26th ed. CLSI supplement M100S (ISBN 1-56238-923-8 [Print]; ISBN 1-56238924-6 [Electronic]). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2016. The data in the interpretive tables in this supplement are valid only if the methodologies in M02-A12—Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard—Twelfth Edition; M07-A10—Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard—Tenth Edition; and M11-A8—Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard— Eighth Edition are followed.read more
Citations
More filters
Journal ArticleDOI
VIM- and IMP-type metallo-β-lactamase-producing Pseudomonas spp. and Acinetobacter spp. in Korean hospitals
TL;DR: The occurrence of acquired metallo-β-lactamase (MBL)–producing bacteria in Korean hospitals was determined and infections produced MBL and had alleles of blaVIM-2 or blaIMP-1.
Journal ArticleDOI
Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia.
Hande Aydemir,Deniz Akduman,Nihal Pişkin,Füsun Cömert,E. Horuz,A. Terzi,Furuzan Kokturk,T. Ornek,Güven Çelebi +8 more
TL;DR: The results suggest that the combination of colistin with rifampicin may improve clinical and microbiological outcomes of VAP patients infected with A. baumannii.
Journal ArticleDOI
Resistance to Colistin Associated with a Single Amino Acid Change in Protein PmrB among Klebsiella pneumoniae Isolates of Worldwide Origin
Aurélie Jayol,Laurent Poirel,Adrian Brink,Maria Virginia Villegas,Mesut Yilmaz,Patrice Nordmann +5 more
TL;DR: A key amino acid located in the PmrB protein is identified as being responsible for the overexpression of pmrCAB and pmrHFIJKLM operons, leading to resistance to colistin.
Journal ArticleDOI
Antibiotic Coresistance in Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae and In Vitro Activity of Tigecycline
María-Isabel Morosini,María García-Castillo,Teresa M. Coque,Aránzazu Valverde,A. Novais,Elena Loza,Fernando Baquero,Rafael Cantón +7 more
TL;DR: Tigecycline, lacking cross-resistance with other compounds, could represent an opportunity to reduce the intensity of selection for ESBL-producing organisms derived from the use of other antimicrobial agents, however, this in vitro promise requires support from clinical studies.
Journal ArticleDOI
Excess Costs and Utilization Associated with Methicillin Resistance for Patients with Staphylococcus aureus Infection
Gregory A. Filice,John A. Nyman,Catherine Lexau,Christine H. Lees,Lindsay A. Bockstedt,Kathryn Como-Sabetti,Lindsey Lesher,Ruth Lynfield +7 more
TL;DR: Resistance to methicillin in S. aureus was independently associated with increased costs and effective antimicrobial stewardship and infection prevention programs are needed to prevent these costly infections.